<DOC>
	<DOCNO>NCT00458055</DOCNO>
	<brief_summary>A low level plasma high-density lipoprotein ( HDL ) cholesterol , `` good cholesterol '' , common lipid abnormality observe patient premature atherosclerotic cardiovascular disease . HDL carry excess cholesterol peripheral tissue liver metabolize excrete , process know reverse cholesterol transport . Epidemiological study show inverse correlation plasma level HDL cholesterol risk cardiovascular disease . An increase plasma HDL cholesterol level 1 mg/dL may reduce risk cardiovascular disease 2 3 % . The standard care treatment low level HDL cholesterol : 1 ) lifestyle modification include exercise , smoke cessation , weight control , moderate alcohol intake decrease dietary fat intake - patient encourage follow lifestyle modification ; 2 ) medication raise HDL cholesterol . Currently use medication treat lipid disorder increase , extent , HDL cholesterol . These include niacin ( vitamin B3 ) , fibric acid derivative ( fibrates ) statin . However data effect medication severe case HDL deficiency . This project aim determine whether currently available medication , use standard medical practice treatment lipoprotein disorder , substantially increase HDL cholesterol severe case HDL deficiency .</brief_summary>
	<brief_title>High-Density Lipoprotein ( HDL ) Treatment Study</brief_title>
	<detailed_description>Objective rationale . We collect , past 15 year , large group patient familial HDL cholesterol deficiency . In approximately 25 % index probands family study , genetic basis HDL deficiency identify molecular level . Approximately 20 % severe HDL cholesterol deficient patient mutation within ABCA1 gene , mutation apoA-I SMPD1 gene also identify . In present study , wish determine whether conventional lipid-regulating medication substantially increase HDL cholesterol patient severe HDL deficiency . Anecdotal report clinic suggest patient ABCA1 mutation respond currently available medication ; thoroughly ascertain protocol . In addition , examine patient genetic HDL deficiency familial form ( gene yet identify ) provide insight treatment option patient . We feel important first whether currently recommend medication effectively raise HDL cholesterol patient . Study subject . The subject include patient familial HDL deficiency ( HDL cholesterol &lt; 5th percentile age gender , least one degree relative affect ) HDL deficiency well-defined genetic mutation . We expect approximately 20-25 patient enter study . Patients exclude least one follow criterion present : - Triglycerides ≥ 5 mmol/L - Diabetes - Severe obesity ( BMI ≥ 30 ) - Alcohol intake &gt; 21 drinks/week - Untreated disease ( thyroid , hepatic renal ) Study procedure . Patients treat accord current lipid treatment guideline ( McPherson R , Frohlich J , Fodor G , Genest J. Canadian Cardiovascular Society position statement : recommendation diagnosis treatment dyslipidemias prevention cardiovascular disease . Can J Cardiol 2006 ; 22:913-927 ) use three follow medication ( separately combination ) : - Lipitor 20 mg - Lipidil 200 mg - Niaspan 2 g It note three medication currently use treat patient dyslipidemia represent current `` standard care '' . Statistics . The null hypothesis expect treatment effect increase HDL cholesterol 10 % study sample ( α = 0.05 β = 0.8 ) . Using study design , patient serve his/her control . Differences baseline ( B ) treatment ( T ) period medication examine sudent 's t-test . Protocol . Each treatment period last 8 week ; wash-out period last 4 week . Baseline value ( B1-3 ) take begin treatment period . On-treatment value ( T1-3 ) draw end medication period . At time B ( baseline ) T ( treatment ) patient examine : - Body mass index ( weight height ) - Blood pressure - Symptoms ischemic heart disease - Hepatic function - Myopathic symptoms The following blood test perform : - Total cholesterol - Triglycerides - HDL cholesterol - LDL cholesterol - ApoA-I , apoB - ALT , CK At time B1 blood also collect determination : - TSH - Creatinine - ALT - Blood glucose In addition , blood use examine ability patient 's HDL plasma promote cellular cholesterol efflux , use vitro model well establish laboratory . Cellular cholesterol efflux test efficiency apoA-I lipidation cell formation HDL particles . This provide general index functional status HDL particles body .</detailed_description>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Genetic Diseases , Inborn</mesh_term>
	<mesh_term>Hypoalphalipoproteinemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>HDL deficiency ( HDLcholesterol &lt; 5th percentile , age gendermatched ) Triglycerides ≥ 5 mmol/L Diabetes Severe obesity ( BMI ≥ 30 ) Alcohol intake &gt; 21 drinks/week Untreated disease ( thyroid , hepatic renal )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Lipid lower agent</keyword>
	<keyword>Drug treatment</keyword>
	<keyword>Statin</keyword>
	<keyword>Fibrate</keyword>
	<keyword>Niacin</keyword>
	<keyword>Cellular cholesterol efflux</keyword>
</DOC>